OverviewChartNewsTraderScreen

Goldman Sachs Discount Zert TDXP .../  DE000GG5M381  /

EUWAX
1/23/2025  8:51:58 AM Chg.0.00 Bid1:54:38 PM Ask1:54:38 PM Underlying Strike price Expiration date Option type
30.04EUR 0.00% 30.02
Bid Size: 2,000		 30.05
Ask Size: 500		 TECDAX - EUR 3/25/2026 Call
GlobeNewswire 7/22/2024 MiddleGround Capital enters into Investment Agreement with STEMMER IMAGING AG and announces intentio...
GlobeNewswire 6/12/2018 Software AG acquires Technology Scale-up TrendMiner for analysis and visualization of time series da...
GlobeNewswire 12/20/2016 Medigene announces outlicensing of AAVLP technology
GlobeNewswire 12/13/2016 MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or...
GlobeNewswire 12/6/2016 Medigene AG to be included in TecDAX Index
GlobeNewswire 12/6/2016 MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 201...
GlobeNewswire 12/6/2016 MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016
GlobeNewswire 11/28/2016 MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing Authorisation Application Fo...
GlobeNewswire 11/17/2016 MorphoSys Announces That Its Licensee Janssen Has Submitted Biologics License Application For Guselk...
GlobeNewswire 11/15/2016 MorphoSys Raises EUR 115 million in Private Placement
GlobeNewswire 11/15/2016 Ad hoc: MorphoSys Raises EUR 115 million in Private Placement
GlobeNewswire 11/15/2016 MorphoSys to Raise Capital via a Private Placement of New Shares
GlobeNewswire 11/15/2016 Ad hoc: MorphoSys to Raise Capital via a Private Placement of New Shares
GlobeNewswire 11/15/2016 MorphoSys Announces That Its Licensee Janssen Has Presented Positive Clinical Data of Guselkumab in ...
GlobeNewswire 11/14/2016 MorphoSys to Present at Upcoming Investor Conferences
GlobeNewswire 11/8/2016 Anke Linnartz joins MorphoSys as Head of Corporate Communications and Investor Relations
GlobeNewswire 11/7/2016 MorphoSys AG Reports Results for the First Nine Months of 2016
GlobeNewswire 11/3/2016 MorphoSys Announces Presentations of Clinical Data at Upcoming American Society of Hematology (ASH) ...
GlobeNewswire 11/2/2016 MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatol...
GlobeNewswire 10/28/2016 MorphoSys to Host Q3 2016 Conference Call on November 7, 2016
GlobeNewswire 10/20/2016 MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody
GlobeNewswire 10/17/2016 MorphoSys Presents Updated Clinical Results for MOR202 at Medical Conference
GlobeNewswire 10/1/2016 MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Gusel...
GlobeNewswire 10/1/2016 Ad hoc: MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study ...
GlobeNewswire 9/29/2016 MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis